Year-end Sale % OFF 
Abstract
Definitive diagnosis of invasive fungal disease (IFD) remains limited, and nonculture diagnostic tests could improve this. Serologic testing for biomarkers is standardized through commercial manufacture and is gaining widespread application and incorporation into disease-defining guidelines, whereas most molecular assays remain “in-house” with few commercial tests and limited clinical validation. Standardization of molecular testing will need to be genus-specific because different diseases present and progress in various ways, influencing the optimal specimen choice. Methodologic standardization is almost complete for Aspergillus polymerase chain reaction and will be used to determine clinical performance. The new generation of broad-range systems capable of detecting and differentiating fungi may provide the best route to covering the spectrum of IFD, but evaluation is required and will be difficult to achieve for some of the less prevalent IFDs.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
